Deutsch English Français

Contact

EP1423118

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1423118

EP1423118 - METHOD AND COMPOSITION FOR TREATMENT OF CANCER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 03.08.2007 Database last updated on 24.04.2024
Most recent event Tooltip	03.08.2007	Application deemed to be withdrawn	published on 05.09.2007 [2007/36]
Applicant(s)	For all designated states UNISEARCH LIMITED Rupert Myers Building, Level 2, Gate 14, Barker Street, UNSW Sydney, NSW 2052 / AU
	[N/P]
Former [2004/23]	For all designated states UNISEARCH LIMITED Rupert Myers Building, Level 2, Gate 14, Barker Street, UNSW Sydney, NSW 2052 / AU
Inventor(s)	01 / MORRIS, David, Lawson 950 Forest Road Lugarno, New South Wales 2217 / AU
	02 / POURGHOLAMI, Mohammad, Hossein 16/276 Bunnerong Road Hillsdale, New South Wales 2136 / AU
	[2004/23]
Representative(s)	Müller-Boré & Partner Patentanwälte PartG mbB Friedenheimer Brücke 21 80639 München / DE
	[N/P]
Former [2004/23]	Müller-Boré & Partner Patentanwälte Grafinger Strasse 2 81671 München / DE
Application number, filing date	02748440.1	16.07.2002
	[2004/23]
	WO2002AU00954
Priority number, date	AU2001PR06443	17.07.2001 Original published format: AU PR644301
	[2004/23]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO03007957
	Date:	30.01.2003
	Language:	EN
	[2003/05]
	Type:	A1 Application with search report
	No.:	EP1423118
	Date:	02.06.2004
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 30.01.2003 takes the place of the publication of the European patent application.
	[2004/23]
Search report(s)	International search report - published on:	AU	30.01.2003
	(Supplementary) European search report - dispatched on:	EP	08.02.2006
Classification	IPC:	A61K31/498, A61K47/44, A61P35/04	[2004/23]
	CPC:	A61K47/44 (EP,US); A61K31/498 (EP,KR,US); A61K47/14 (EP,US); A61K9/0019 (EP,US); A61P35/00 (EP); A61P35/04 (EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR [2004/23]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	VERFAHREN UND ZUSAMMENSETZUNG FÜR DIE KREBSBEHANDLUNG	[2004/23]
	English:	METHOD AND COMPOSITION FOR TREATMENT OF CANCER	[2004/23]
	French:	PROCEDE ET PREPARATION DE TRAITEMENT DU CANCER	[2004/23]
Entry into regional phase	05.02.2004	National basic fee paid
	05.02.2004	Search fee paid
	05.02.2004	Designation fee(s) paid
	05.02.2004	Examination fee paid
Examination procedure	06.12.2002	Request for preliminary examination filed International Preliminary Examining Authority: AU
	30.01.2004	Amendment by applicant (claims and/or description)
	05.02.2004	Examination requested [2004/23]
	18.08.2006	Despatch of a communication from the examining division (Time limit: M06)
	01.03.2007	Application deemed to be withdrawn, date of legal effect [2007/36]
	10.04.2007	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2007/36]
Fees paid	Renewal fee
	14.07.2004	Renewal fee patent year 03
	13.07.2005	Renewal fee patent year 04
	12.07.2006	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]ZA928419 ;
		[Y]GB1081551 (MICHEL MARIE ANDRE GUERBET) [Y] 1-20 * the whole document *;
		[Y]US4578391 (KAWATA HIROITSU [JP], et al) [Y] 1-20 * the whole document *;
		[Y]EP0193936 (SUMITOMO PHARMA [JP]) [Y] 1-20 * abstract * * column 7, line 62 - line 68 * * column 8 * * column 9, line 6 - line 7 * * column 13, line 38 - line 68 * * column 14, line 1 - line 24 *;
		[Y]EP0676201 (ADCOCK INGRAM PHARMA [ZA]) [Y] 1-20 * the whole document *;
		[YD]WO9956697 (UNISEARCH LTD [AU], et al) [YD] 1-20 * the whole document *;
		[XY]WO0017212 (JOMAA HASSAN [DE]) [X] 16-19 * page 14, paragraphs 3,4,8,9 * * page 15, line 25 * * page 16, paragraph 4 * [Y] 10-13,15;
		[Y] - DATABASE WPI, 0, Derwent World Patents Index, vol. 1994, no. 28, Database accession no. 1994-235028, XP002364923 & ZA9208419 A 19940525 (UNIV PRETORIA) [Y] 1-20 * abstract *
		[Y] - O'REILLY J R ET AL, "THE EFFECT OF MIXED MICELLAR SYSTEMS, BILE SALT/FATTY ACIDS, ON THE SOLUBILITY AND INTESTINAL ABSORPTION OF CLOFAZIMINE (B663) IN THE ANAESTHETISED RAT", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, (1994), vol. 109, no. 2, ISSN 0378-5173, pages 147 - 154, XP008058446 [Y] 16-19 * the whole document * DOI: http://dx.doi.org/10.1016/0378-5173(94)90142-2
		[Y] - KONNO T, "TARGETING CHEMOTHERAPY FOR HEPATOMA: ARTERIAL ADMINISTRATION OF ANTICANCER DRUGS INVOLVED IN LIPIODOL", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (1992), vol. 28, no. 2/3, ISSN 0959-8049, pages 403 - 409, XP008058468 [Y] 1-14,16-20 * the whole document * DOI: http://dx.doi.org/10.1016/S0959-8049(05)80063-2
		[Y] - KONNO T ET AL, "TARGETED CHEMOTHERAPY FOR UNRESECTABLE PRIMARY AND METASTATIC LIVER CANCER", ACTA ONCOLOGICA, XX, XX, (1994), vol. 33, no. 3, pages 133 - 137, XP008058449 [Y] 1-14,16-20 * the whole document *
		[Y] - MATHUR A ET AL, "EFFECT OF DIETARY FAT ON TISSUE DISPOSITION OF CLOFAZIMINE IN MICE RECEIVING THE DRUG ORALLY AS SUSPENSION IN OILS", INDIAN JOURNAL OF PHARMACOLOGY, XX, XX, (1997), vol. 29, no. 4, ISSN 0253-7613, pages 262 - 265, XP008058453 [Y] 1-9 * the whole document, especially page 58 left column 3.3.1 ; page 60 3.3.3 ; page 63 Table 2 ; Figure 3 curves PLC *
		[A] - VAN RENSBURG C E ET AL, "Riminophenazine compounds: pharmacology and anti-neoplastic potential.", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. JAN 1997, (199701), vol. 25, no. 1, ISSN 1040-8428, pages 55 - 67, XP002364921 [A] 16-19 * the whole document * DOI: http://dx.doi.org/10.1016/S1040-8428(96)00229-6
	International search	[X] - RUFF P. ET AL., "A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma", ANNALS OF ONCOLOGY, (199802), vol. 9, no. 2, pages 217 - 219, XP002997317 DOI: http://dx.doi.org/10.1023/A:1008204911774
		[X] - VAN RENSBURG C.E.J. ET AL., "The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and non-oxidative mechanisms", CANCER RESEARCH, (199301), vol. 53, pages 318 - 323, XP002997346
		[X] - VAN NIEKERK E. ET AL., "Tetramethylpiperidine-substitued phenazines inhibit the proliferation of intrinsically multidrug resistant carcinoma cell lines", INVESTIGATIONAL NEW DRUGS, (200108), vol. 19, no. 3, pages 211 - 217, XP002997318 DOI: http://dx.doi.org/10.1023/A:1010691714635
		[X] - SRITHARAN M., "Studies on the tissues distribution of liposome-associated clofazimine, an antileprosy drug", METH. FIND. EXP. CLIN. PHARMACOL., (199303), vol. 15, no. 2, pages 107 - 111, XP002997347
		[X] - PATEL V.B. ET AL., "A topical dosage form of liposomal clofazimine: research and clinical implications", PHARMAZIE, (199906), vol. 54, no. 6, pages 448 - 451, XP000828549
		[X] - HOLDINESS M.R., "Clinical pharmacokinetics of clofazimine. A review", CLINICAL PHARMACOKINETICS, (1989), vol. 16, pages 74 - 85, XP002997348
		[X] - DATABASE WPI, 1, Derwent World Patents Index, vol. 1994, no. 28, Database accession no. 1994-235028, XP002997319 & ZA9208419 A 19940525 (UNIV. PRETORIA)

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p